News & Analysis as of

Antitrust Provisions Today's Popular Updates Regulatory Requirements

Alston & Bird

EC’s First In-Depth FSR Merger Decision – Initial Takeaways for Dealmakers

Alston & Bird on

Our Antitrust Team examines the European Commission’s first conditional merger clearance under the Foreign Subsidies Regulation (FSR) and how it provides key insights into how foreign financial contributions impact...more

Baker Botts L.L.P.

Saudi Arabia Responds to Investors with Revised Merger Guidelines Addressing Practical Needs

Baker Botts L.L.P. on

The Saudi General Authority for Competition (GAC) continues to develop its antitrust and competition regulatory framework to bring it in line with international standards. These efforts are part of the Kingdom’s broader goal...more

Morgan Lewis

M&A Considerations Across the Technology Sector

Morgan Lewis on

Technology is quickly becoming one of the most active and dynamic sectors for mergers and acquisitions (M&A) in 2025. Despite a macro environment filled with uncertainty, technology deal activity reflects an appetite for...more

Paul Hastings LLP

Check-Up and Diagnosis: The Ongoing Scrutiny of Private Equity Healthcare Investments

Paul Hastings LLP on

In 2024 alone, over 676 private equity firms and related investors acquired healthcare companies or related assets. The growing influence of private equity in the healthcare industry has not gone unnoticed on either of the...more

Thomas Fox - Compliance Evangelist

Daily Compliance News: May 1, 2025, The 100 Days of Corruption Edition

Welcome to the Daily Compliance News. Each day, Tom Fox, the Voice of Compliance, brings you compliance-related stories to start your day. Sit back, enjoy morning coffee, and listen to the Daily Compliance News. All, from the...more

Fish & Richardson

Biosimilars 2022 Year in Review

Fish & Richardson on

2022 heralded the next chapter for biosimilars in the United States, including U.S. Food and Drug Administration approval of biosimilars in new therapeutic areas, additional interchangeable designations, and litigation...more

Fish & Richardson

Biosimilars 2021 Year in Review

Fish & Richardson on

2021 saw several important milestones in the biosimilars space, including the much anticipated first interchangeable designations by FDA and the approval of the first ophthalmology biosimilar. The biosimilar market also...more

Hogan Lovells

[Webinar] IoT in the EU: Lessons from COVID-19, and next steps for liability and regulation - September 15th, 3:30 pm - 4:15 pm...

Hogan Lovells on

Connected products remain in focus during 2020. Now more than ever before, they bring new opportunities to our homes, work, travel, and health care. In this webinar our leading cross-border products law team discuss the...more

Hogan Lovells

FTC uses “study authority” to review past non-HSR acquisitions

Hogan Lovells on

On 11 February 2020 Federal Trade Commission (FTC) announced that it has issued Special Orders to five large technology firms requiring them to “provide information about prior acquisitions not reported to the antitrust...more

Robins Kaplan LLP

Financial Daily Dose 2.12.2020 | Top Story: Big Tech Antitrust Update

Robins Kaplan LLP on

Big-Tech/Antitrust Update: the FTC has demanded information from Amazon.com Inc., Apple Inc., Facebook Inc., Microsoft Corp., and Alphabet Inc. regarding acquisitions of small firms over the past 10 years that may have been...more

10 Results
 / 
View per page
Page: of 1

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
- hide
- hide